Trigemina announced the results of a small clinical trial of intranasal oxytocin for headache. Twenty-five patients with chronic daily headache who didn't get relief from any available remedies received either oxytocin or a placebo.
While 47 percent of people treated with oxytocin reported at least a 50 percent reduction in pain, only 11 percent of those getting the placebo got relief.
According to the press release, Trigemina researchers don't think it's as simple as oxytocin opening up blood vessels in the head. Instead, inhalants seem to be able to deliver medication to the trigeminal nerve and other parts of the central nervous system.
According to the company, "Trigemina, Inc. exploits a newly discovered pathway that allows for targeting of the trigeminal nerves and central nervous system, allowing direct access to pain mediating sites and minimizing off-target side effects. Trigemina’s drug development pipeline includes intranasal oxytocin (TI-001) and TI-002, which may offer an alternative for the massive opiate market."